University of Cologne | MedPath Search

Found 407 clinical trials|View Analysis

Sort by:

Need a comprehensive medical report on "University of Cologne"?

Analyze the latest clinical research and treatment options

Summarize scientific findings from medical journals

Learning Diagnostic Skills Online (German: Diagnostik Skills Online Lernen)

Not Applicable

Completed

Conditions: Diagnosis, Psychiatric

Interventions: Behavioral: blended learning
Behavioral: teaching format as usual

First Posted Date: 2022-03-24

Last Posted Date: 2022-03-24

Lead Sponsor: Ruhr University of Bochum

Target Recruit Count: 350

Registration Number: NCT05294094

Locations: 🇩🇪
Philipps University of Marburg, Marburg, Hesse, Germany
🇩🇪
Ruhr-University Bochum, Bochum, North Rhine-westphalia, Germany
🇩🇪
University of Cologne, Cologne, North Rhine-westphalia, Germany

Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Phase 2

Active, not recruiting

Conditions: Head and Neck Cancer

Interventions: Drug: Retifanlimab
Drug: INCAGN02385
Drug: Placebo
Drug: INCAGN02390

First Posted Date: 2022-03-18

Last Posted Date: 2025-04-24

Lead Sponsor: Incyte Biosciences International Sàrl

Target Recruit Count: 176

Registration Number: NCT05287113

Locations: 🇬🇷
Saint Lukas Clinic, Thessaloniki, Greece
🇵🇱
Przychodnia Lekarska Komed Roman Karaszewski, Konin, Poland
🇵🇱
Nzoz Provita Prolife Centrum Medyczne, Tomaszow Mazowiecki, Poland

and more 86 locations

Analysis of Factors Determining Increase of Serum Sodium in Hyponatremic Patients

Completed

Conditions: Hyponatremia

First Posted Date: 2022-03-14

Last Posted Date: 2023-05-19

Lead Sponsor: University of Cologne

Target Recruit Count: 3460

Registration Number: NCT05277584

Locations: 🇩🇪
Department II of Internal Medicine,University of Cologne, Cologne, Germany

A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma

Phase 3

Recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Daratumumab
Drug: Bortezomib
Drug: Lenalidomide
Drug: Dexamethasone
Drug: Cilta-cel
Drug: Cyclophosphamide
Drug: Fludarabine

First Posted Date: 2022-02-25

Last Posted Date: 2025-05-28

Lead Sponsor: Stichting European Myeloma Network

Target Recruit Count: 750

Registration Number: NCT05257083

Locations: 🇺🇸
University of Arkansas, Little Rock, Arkansas, United States
🇺🇸
City of Hope, Duarte, California, United States
🇺🇸
UC San Diego Health Moores Cancer Center, San Diego, California, United States

and more 106 locations

Impact of Face Masks on 6MWD in Patients With Pulmonary Hypertension

Not Applicable

Completed

Conditions: Pulmonary Hypertension

Interventions: Diagnostic Test: six-minutes-walking test

First Posted Date: 2022-02-25

Last Posted Date: 2022-07-21

Lead Sponsor: University Hospital of Cologne

Target Recruit Count: 122

Registration Number: NCT05256082

Locations: 🇩🇪
University Hospital of Cologne, Cologne, Germany

Patient Empowerment for Major Surgery Preparation @ Home

Completed

Conditions: Transthoracic Esophagectomy

Interventions: Other: Prehabilitation program

First Posted Date: 2021-12-22

Last Posted Date: 2024-06-17

Lead Sponsor: University of Cologne

Target Recruit Count: 26

Registration Number: NCT05167682

Locations: 🇩🇪
University Hospital of Cologne, Cologne, Germany

Assessing Immune Response of Different COVID-19 Vaccines in Older Adults

Phase 2

Completed

Conditions: Prevention of COVID-19

Interventions: Biological: Comirnaty(BTN162b2)
Biological: Comirnaty (BTN162b2)
Biological: Spikevax (mRNA-1273)

First Posted Date: 2021-12-16

Last Posted Date: 2025-05-20

Lead Sponsor: Oliver Cornely, MD

Target Recruit Count: 323

Registration Number: NCT05160766

Locations: 🇩🇪
University Hospital Frankfurt, Frankfurt, Germany
🇩🇪
Hannover Medical School Hospital, Hannover, Germany
🇩🇪
University Hospital Cologne, Cologne, Germany

and more 6 locations

Fight INflammation to Improve Outcome After Aneurysmal Subarachnoid HEmorRhage

Phase 3

Recruiting

Conditions: Aneurysmal Subarachnoid Hemorrhage

Interventions: Drug: Placebo
Drug: Dexamethasone

First Posted Date: 2021-11-24

Last Posted Date: 2023-05-10

Lead Sponsor: University Hospital, Bonn

Target Recruit Count: 334

Registration Number: NCT05132920

Locations: 🇩🇪
Otto von Guericke University Magdeburg, Magdeburg, Sachsen-Anhalt, Germany
🇩🇪
University Hospital Bonn, Bonn, NRW, Germany
🇩🇪
University Hospital Leipzig, Leipzig, Sachsen, Germany

and more 10 locations

Setrusumab vs Placebo for Osteogenesis Imperfecta

Phase 2

Active, not recruiting

Conditions: Osteogenesis Imperfecta

Interventions: Biological: Setrusumab
Other: Placebo

First Posted Date: 2021-11-18

Last Posted Date: 2025-04-25

Lead Sponsor: Ultragenyx Pharmaceutical Inc

Target Recruit Count: 182

Registration Number: NCT05125809

Locations: 🇺🇸
Nationwide Children's Hospital- Ohio State University College of Medicine, Columbus, Ohio, United States
🇺🇸
Arkansas Children's Hospital, Little Rock, Arkansas, United States
🇺🇸
Nemours/ Alfred i. duPoint Hospital for Children, Wilmington, Delaware, United States

and more 88 locations

Merit WRAPSODY™ Endoprosthesis for Treatment of Stenosis or Occlusion (WRAP)

Recruiting

Conditions: Venous Stenosis
Venous Occlusion

First Posted Date: 2021-09-30

Last Posted Date: 2024-11-20

Lead Sponsor: Merit Medical Systems, Inc.

Target Recruit Count: 500

Registration Number: NCT05062291

Locations: 🇬🇷
The General University Hospital of Patras, Río, Greece
🇳🇿
Te Toka Tumai Auckland, Auckland, New Zealand
🇳🇿
Te Whatu Ora Health NZ Waitemata, Auckland, New Zealand

and more 37 locations